Breakthrough Solutions for Effective Therapies
Oncology
Anti-Cancer Solutions Targeting metastasis, failure and drug resistance
Obesity
Preventing cancers by Treating Obesity
Viral Infection
Example : targeting adipose tissue HIV reservoir and Covid19
About us
THERANOVIR is a young innovative Health-Tech company of Research and Development of breakthrough therapies in 3 fields of closely related pathologies, Cancer, Obesity and associated metabolic diseases and Infectious Diseases by targeting a platform of signaling pathways regulated by the protein complex NRP-1/OBR, newly discovered by the CEO/CSO Dr. Zakia BELAID-SANDAL (PhD). THERANOVIR benefits from a global and exclusive license from INSERM transfert for the valuation of 2 families of granted patents in Europe, United States and Japan. THERANOVIR filed its own patents in January 2023.
THERANOVIR is developing an immunotherapeutic antibody NOV2 with a unique mode of action through its ability to enter into the nucleus of cancer cells and degrade their DNA in a target-dependent manner based on the NRP-1/OBR complex induced by leptin, without significant genotoxic effect on normal cells and with a very high probability of reactivation of the anti-tumor immune response.
Abstract 3293: Leptin induces breast cancer metastasis through a Neuropilin-1 (NRP-1)/OBR complex
Theranovir rewards
THERANOVIR is a winner of :
- Lab-SHAKER 2017 (Genopole),
- Onco-Entrepreneurs 2018 (Cancer Campus, Villejuif),
- HEC-Challenge+ 2019 (HEC Paris),
- Ilab 2020 (Ministry of education and research),
- Innov’up PIA 2021 (Ile-de-France region) competitions.
- NETVA Start in America 2024
Team
Operational team
Zakia BELAID-SANDAL (PhD)
Co-founder-President / CEO/CSO
17 years of experience in leading and participating in oncology programs in France and abroad
3 co-invented patents
Alexander EGGERMONT
(MD PhD)
Associate/ Scientific/Clinical Advisor
KOL for immuno-onco therapies, experience in leading European cancer institutions
Former General Manager of French Institute of Cancer Gustave ROUSSY
Elie MATTA (PhD)
Assistant Scientific Investigator
PhD in Oncology and Cancer Biology
Co-author of 3 publications in DNA Repair
Advisory Board
Azzedine BOUDJADJA
(MD)
Expert in Clinical Development
Oncology and Infectious diseases area
Former Medical Director at Bayer-Healthcare
Radhia M’KACHER
(PhD)
Expert in molecular oncology and
DNA Repair and Damage
CEO of Cell Environment
Hervé FRIDMAN
(MD PhD)
President of Cancéropôle Ile de France
Deputy Director of CARPEM and KOL for anti-cancer immuno-oncology
Consultants
Christophe de ROMEUF
(PhD)
Expert in monoclonal antibody preclinical studies, data room and team management.
CRBioconsult, France
Alexandre FONTAYNE
(PhD)
Expertise in Drug Design and preclinical R&D
Former President of Biothelis SAS, President and expert of BE4S consulting
They support us
Labels
Contact
Head Office
Pépinière, Genopole entreprise
4 rue Pierre-Fontaine
91000 Evry-Courcouronnes
Laboratory R&D
Pavillon de Recherche 1 /Niv4/p401
Institut Gustave Roussy
Cancer Campus
114 Edouard Vaillant
94800 Villejuif
contact@theranovir.com
Phone
+ 33 1 42 11 60 43